Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Krönke
Christian Krönke, Munich DE
| Patent application number | Description | Published |
|---|---|---|
| 20120128110 | METHOD AND SYSTEM FOR ELIMINATING IMPLEMENTATION TIMING IN SYNCHRONIZATION CIRCUITS - A method and system for eliminating implementation timing with respect to a synchronization circuit. A standard library cell having a pair of dock input pins can be connected with at least two asynchronous dock domains of the synchronization circuit in order to measure a timing signal between the flip-flop latches crossing the asynchronous clock domain. A timing delay with respect to each bit pair of the asynchronous dock domain can be determined utilizing a static analysis approach during a layout phase in order to effectively synchronize the asynchronous dock domain. Each bit pair of the asynchronous dock domain can be checked via a static timing analysis tool in order to thereby improve functional accuracy of the synchronization circuit in a wide range of digital logic designs. | 05-24-2012 |
Martin Krönke, Koln DE
| Patent application number | Description | Published |
|---|---|---|
| 20090300778 | Neutral Sphingomyelinase-E and Its Use - The present invention provides a neutral sphingomyelinase-3 (nSMase3), a nucleic acid encoding said nSMase3, a vector containing said nucleic acid, and cells and non-human organisms transformed or transfected with said nucleic acid sequence or vector. The invention furthermore relates to the use of said nSMase3 as pharmaceutical or diagnostic agent. Test systems for candidate active agents for their therapeutic potential in diseases connected with nSMase3 are also provided. | 12-03-2009 |
Martin Krönke, Koln DE
| Patent application number | Description | Published |
|---|---|---|
| 20090300778 | Neutral Sphingomyelinase-E and Its Use - The present invention provides a neutral sphingomyelinase-3 (nSMase3), a nucleic acid encoding said nSMase3, a vector containing said nucleic acid, and cells and non-human organisms transformed or transfected with said nucleic acid sequence or vector. The invention furthermore relates to the use of said nSMase3 as pharmaceutical or diagnostic agent. Test systems for candidate active agents for their therapeutic potential in diseases connected with nSMase3 are also provided. | 12-03-2009 |
Thomas Gerhard Willi Krönke, Velbert DE
| Patent application number | Description | Published |
|---|---|---|
| 20080280155 | Method of Manufacture of Direct Pressure Laminates - Using a method of direct-pressure laminating employing short cycle presses (low pressure process), one or more impregnated overlays and a non-impregnated decor sheet are laminated to a base material. | 11-13-2008 |
| 20090220808 | Resin composition comprising waste of resin impregnated material - Resin composition comprising ground waste of resin impregnated materials. | 09-03-2009 |
Thomas Gerhard Willi Krönke, Velbert DE
| Patent application number | Description | Published |
|---|---|---|
| 20090220808 | Resin composition comprising waste of resin impregnated material - Resin composition comprising ground waste of resin impregnated materials. | 09-03-2009 |